There are hundreds of brands of sunscreen available in the United States, but not one of them contains an ingredient we all need. Bemotrizinol, a highly effective, broad-spectrum chemical ultraviolet ray blocker, has been available in Europe for decades but absent from U.S. shelves. The regulatory bottleneck was driven by a 2011 U.S. Food and Drug Administration policy classifying sunscreens as drugs. While the classification remains, consumers and innovators can welcome the news that the FDA has officially approved bemotrizinol, effective August 9, 2026. Science News‘s Meghan Rosen provides the coverage.
⛑️ The science: Stability + safety
Bemotrizinol bests legacy sunscreen tech on two major fronts: photostability and safety. Traditional chemical sunscreens such as avobenzone degrade rapidly in sunlight, requiring frequent reapplication and causing skin irritation. The benefit of bemotrizinol is that it is highly photostable, meaning it maintains its efficacy over long durations without breaking down. In theory, that means people can go longer before having to slather it on again. Bemotrizinol effectively blocks UVA rays — the ones that prematurely age skin — along with the sunburn-causing UVB rays legacy ingredients target. While established filters are all safe, bemotrizinol can’t get absorbed into the bloodstream, a sunscreen concern for some social media influencers.
💎 Premiumization pays
The global sunscreen market is projected to exceed $15 billion by 2030, but the U.S.
Not yet a subscriber?
Access to this content requires an Investors Lab subscription. Sign up for a free trial today to explore exclusive, data-backed insights into scientific breakthroughs set to disrupt industries.
